CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services CADTH Reimbursement Review venetoclax
Back to Programs and Services

CADTH Reimbursement Review

venetoclax

Last Updated: December 17, 2020
Result type: Reports
Project Number: PC0239-000
Product Line: Reimbursement Review

Generic Name: venetoclax

Brand Name: Venclexta

Manufacturer: AbbVie Corporation

Therapeutic Area: Acute myeloid leukemia

Indications: In combination with azacitidine or low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Manufacturer Requested Reimbursement Criteria1: In combination with low-dose cytarabine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Submission Type: Initial

Tumour Type: Leukemia

Project Status: Pending

Call for patient/clinician input open: December 17, 2020

Call for patient/clinician input closed: February 12, 2021

Anticipated Date: January 22, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback